Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. März 2020 08:30 ET | Quelle: Celsion CORP

Celsion CEO Issues Letter to Stockholders

LAWRENCEVILLE, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman,...
28. Februar 2020 08:45 ET | Quelle: Celsion CORP

Celsion Corporation Prices $4.8 Million Registered Direct Offering

LAWRENCEVILLE, NJ, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into securities purchase agreements with...
06. Februar 2020 09:25 ET | Quelle: Celsion CORP

Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer

Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy LAWRENCEVILLE, N.J., Feb. 06, 2020 (GLOBE...
04. Februar 2020 08:30 ET | Quelle: Celsion CORP

Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference

Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020 LAWRENCEVILLE, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) --...
18. Dezember 2019 08:00 ET | Quelle: Celsion CORP

Celsion’s New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia

Memorandum of Understanding completed with Chinese government officials in the Yuhang district of Hangzhou, China’s biotech hub, to develop and commercialize innovative cancer therapies starting with...
17. Dezember 2019 08:00 ET | Quelle: Celsion CORP

Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program

Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share Assures Funding Through Major Company Events; Company Provides Guidance on the Timing of Upcoming...
14. November 2019 16:05 ET | Quelle: Celsion CORP

Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update

Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety Monitoring Board (DSMB)...
14. November 2019 08:00 ET | Quelle: Celsion CORP

Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia

Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver...
08. November 2019 08:30 ET | Quelle: Celsion CORP

Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019

Company to Provide Clinical Development Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., Nov. 08, 2019 (GLOBE...
05. November 2019 08:00 ET | Quelle: Celsion CORP

Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer

GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) --...

Vorherige Seite